Affiliation:
1. MedStar Health Research Institute; Hyattsville Maryland
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference96 articles.
1. The cardiovascular biology of glucagon-like peptide-1;Drucker;Cell Metab,2016
2. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors;Nauck;Diabetes Obes Metab,2016
3. Aroda VR Arulandu JR Cannon AJ 2017 Insulin/GLP-1 receptor agonist combination therapy for the treatment of type 2 diabetes: are two agents better than one?
4. U.S. Food and Drug Administration Guidance for industry: diabetes mellitus -- evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes 2008 https://www.fda.gov/downloads/Drugs/.../Guidances/ucm071627.pdf
5. Evolution of exenatide as a diabetes therapeutic;Bhavsar;Curr Diabetes Rev,2013
Cited by
197 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction‐associated steatotic liver disease: A prospective, multicentre, observational study;Diabetes, Obesity and Metabolism;2024-09-02
2. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review;Cureus;2024-09-01
3. Efficacy and Safety of Escalating the Dose of Oral Semaglutide from 7 to 14 mg: A Single-Center, Retrospective Observational Study;Diabetes Therapy;2024-08-07
4. Safety of native glucose-dependent insulinotropic polypeptide in humans;Peptides;2024-07
5. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study;Journal of Hepatology;2024-07